ClinicalTrials.gg
RecruitingNCT06761144Updated Jan 7, 2025

Pulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department

An observational study in Pulmonary Thromboembolisms, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Pulmonary Embolism with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Pulmonary Embolism · Italy.

Planned enrollment
17th of 28
500 · median 623
Started
2024
the only one that year
Observational
28 of 57
6 open now
Registered
55th of 57
by date
Lead sponsor
5 of 57
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Among the 57 studies in Pulmonary Embolism with a site in Italy, this one is the 17th largest by planned enrollment of the 28 observational ones that give a count, is the only one that started in 2024, is one of 28 observational ones, and was the 55th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

6 of the 57 studies in Pulmonary Embolism with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Pulmonary Embolism with a site in Italy, or all of them as a file.
02

Study summary

Pulmonary thromboembolism is a frequent complication of cancer; in some cases, it is diagnosed occasionally during diagnostic examinations as part of the regular follow-up of the disease. Not all patients diagnosed with thromboembolism present symptoms; therefore, after appropriate investigations during observation in the emergency room and/or a short hospitalisation in Emergency Medicine, they could be discharged home, avoiding lengthy hospitalisations that would have a considerable impact on their health and psychological condition.

The goal of this observational study is to compare the efficacy of several assessment scales for use by physicians to identify patients at low risk of developing serious complications of pulmonary embolism within 30 days of diagnosis, in order to be able to identify a group of low-risk patients who could be discharged early from the emergency department/emergency medicine safely.

What does participation in this study entail compared to the normal care you receive and what are your responsibilities as a participant? At the time of patient enrolment in the emergency room/emergency medicine, the data necessary for the calculation of 6 scoring systems will be collected, which will take approximately 5 minutes.

The patient enrolled in the study will be contacted by telephone in order to assess the state of health; the call will take approximately 1 minute and will take place 30 days after access to the emergency room.

Participation in the study does not entail any obligation or restriction, nor will it be charged for.

Read the detailed description

Cancer patients are at increased risk of developing thromboembolic complications, including pulmonary thromboembolism (PTE), with an annual incidence of 1:200. Not all patients with PTE present with symptoms suggestive of the disease, and nowadays, thanks in part to the technological development of radiological techniques that make it possible to visualise as far as the subsegmental branches of the pulmonary vasculature, the diagnosis of pulmonary embolism is steadily increasing. Therefore, we are increasingly seeing the diagnosis of Incidental Pulmonary Embolism (IPE), defined as 'an unsuspected pulmonary artery filling defect identified during CT scans performed for other reasons, usually during screening and follow-up of cancer pathology'. Patients with IPE are often asymptomatic, although in some cases, further investigation of the history and complaints reported by the patient may reveal some symptoms compatible with PTE.

The incidence of IPE in cancer patients ranges from 1.6 to 7.3%. In this study, patients who presented to the Emergency Department during the period from 01.01.2015 to 31.12.2019 will be consecutively enrolled in a retrospective manner and prospectively patients presenting to the Emergency Department for a period of two years from the approval of the study by the Ethics Committee and subsequent clearance by the Director General with a diagnosis of PTE in the course of active onco-haematological disease (pathology followed in an oncological/haematological and/or metastatic setting).

A 30 day follow-up will be carried out in order to record any major adverse events, like death, respiratory failure, or re-hospitalisation.

The study is observational, non-interventional. Patients will be treated according to clinical practice in accordance with the judgement of the physician.

The primary objective is to evaluate existing and used prognostic scores (HESTIA, PESI, sPESI, POMPE-C, EPIPHANY Index, RIETE) in oncological patients with incidental pulmonary embolism in order to identify the one with the greatest effectiveness in identifying patients at low risk of major adverse events at 30 days, and therefore safely discharged early from the emergency department.

The secondary objective is to identify, in the group of cancer patients with pulmonary embolism (incidental and symptomatic), which score among those used has the best performance in identifying patients at low risk of major adverse events at 30 days, in order to identify a group of patients who can be discharged early and safely.

The outcome to be assessed is 30-day mortality in patients identified as low risk with the scores used. In addition, evaluate a composite endpoint at 30 days: hospitalisation for PTE diagnosis-related problems/respiratory failure-related illness/mortality at 30 days.

It should be noted that the diagnosis of acute respiratory failure will be made according to the diagnostic criteria known in the literature. This diagnosis imposes the need for oxygen therapy, so the patient with respiratory failure will not be discharged home, necessarily requiring hospitalisation, which is an adverse event for the proposed study.

Outcomes will be assessed using computerised records and PS reports. Patients over 18 years of age attending the General Hospital / Emergency Medicine IRCCS AOU of Bologna Policlinico di S.Orsola with a diagnosis of PTE and onco-haematological pathology will be included. The duration of the study is estimated to be 3 years: 6 months for retrospective data collection, 24 months for prospective enrolment and 6 months for data processing.

It should be noted that patients will be enrolled at the first admission to the Emergency Department, therefore they will be in charge of the Emergency Department and not in an in-patient setting. The enrolled patients could be retained in the OBI regime (always afferent to the Emergency Department) to complete the basic diagnostic-therapeutic procedure before eventual admission to a medical, intensive-sub-intensive ward or discharge to home. Any admission to Emergency Medicine, following discharge from the Emergency Department, will be considered as admission to an internist environment.

Patient characteristics will be reported as mean +/- standard deviation for continuous variables and as numerosity and frequency for categorical variables. Sensitivity, specificity, positive and negative predictive values will be calculated for each score. Monovariate statistics using Kaplan Meier curves will be used to assess the association of each score with 30-day mortality. In addition, ROC (Receiver-operating Characteristic) curve analysis will be used to evaluate the performance of each score. Statistical significance will be defined for values of p\<0.05 and analyses will be conducted using SPSS version 28 software (IBM Corp., Armonk, NY, USA).

03

Conditions studied

  • Pulmonary Thromboembolisms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with active oncohematological pathology, over 18 years of age, with a diagnosis of pulmonary embolism attending the Emergency Department of the IRCSS Azienda Ospedaliero-Universitaria di Bologna

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of pulmonary embolism (symptomatic and/or incidental)
  • Active onco-haematological disease (disease followed in oncological/haematological and/or setting)
  • to the study

Exclusion criteria

Exclusion Criteria:

  • Patients returning to the Emergency Department for complications related to previously diagnosed pulmonary embolism
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluate mortality in patients at low risk of major adverse events (death/respiratory failure/hospitalisation)

    The primary objective is to evaluate the already existing and used prognostic scores (HESTIA, PESI, sPESI, POMPE-C, EPIPHANY Index, RIETE) in cancer patients with incidental pulmonary embolism in order to identify the one with the greatest effectiveness for identifying patients at low risk of major adverse events at 30 days, who can therefore be discharged early and safely from the emergency department.

    Time frame: From enrollment to the follow-up at 30 days

07

Study locations

1 of 1 sites recruiting
  • Eleonora Tubertini
    Bologna, 40138, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 35 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2024
First posted
Jan 7, 2025
StartActual
Jul 13, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761144
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jul 13, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jan 7, 2025

Study contacts

Eleonora Tubertini, MD
Contact
eleonora.tubertini@aosp.bo.it
+39 051943435
Eleonora Tubertini, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion